Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017

NCT05185388 | Active Not Recruiting

• 1 other identifier: RS154-ODR-BPS
• Study Type: observational
• Target: 45,831
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a population-based, patient-level analysis of colon and ovarian cancer diagnoses in England over a 2-year period using a dataset created by linking NCRAS and NHS digital datasets. Our analyses will look into inequalities in the diagnostic and treatment pathway, and inequalities in treatment received, for those diagnosed with colon and ovarian cancer between 2016-2017.

Conditions

Treatment Related Cancer; Diagnoses Disease; Equality, Gender

Keywords

Socioeconomic Inequalities

Outcome Measures

Primary Outcomes (2)

• Inequalities in time to diagnosis and/or treatment

  Any differences in time to diagnosis or treatment of colon or ovarian cancer, adjusting for important factors

  January 2016 - December 2017

• Inequalities in treatments received

  Any differences in treatments received for colon or ovarian cancer, adjusting for important factors

  January 2016 - December 2017

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with colon and ovarian cancer diagnosed between 01/01/2016 and 31/12/2017 in England will be considered for inclusion in the study, according to specific inclusion and exclusion criteria.

You may qualify if:

• All patients resident in England and aged 18-99 diagnosed with colon cancer (ICD10 C18) or ovarian cancer (ICD10 C48, C56, C57 and D39,1) where the date of diagnosis is between 01/01/2016 and 31/12/2017.

You may not qualify if:

• Patients with cancers of the appendix (C18.1) will be excluded.
• Male patients with ovarian cancer.
• Borderline ovarian tumours (ICD-10 site code of C56x, C57x or C48x where the morphology code is: 8442, 8444, 8451, 8463, 8473, 8472 or 8462) and (ICD-10 site code D39.1 where the morphology code is 8144, 8260, 8313, 8380, 8381, 8440, 8441, 8460, 8470, 8480, 8481, 9000, 9013, 9014 or 9015).
• Sarcomas are excluded (where the morphology code is: 8693, 8800-8806, 8963, 8990-8991, 9040-9044, 8810, 8811-8921, 9120-9373, 9490, 9500, 9530-9582).
• Patients diagnosed with any prior invasive primary malignancies (ICD10 C00-97x), where the date of diagnosis of such prior invasive malignancies precedes the diagnosis date of the first qualifying tumour. Patients with a synchronous diagnosis on the same day as their qualifying tumour will be included within the sample population.
• Incomplete registrations excluded.

Sponsors & Collaborators

• University of Hull: lead

Study Sites (1)

Hull York Medical School

Hull, Humberside, HU6 7TS, United Kingdom

Location

Related Publications (1)

• Pickwell-Smith BA, Paton LW, Soyiri I, Lind M, Macleod U. Are there inequalities in ovarian cancer diagnosis and treatment in England? A population-based study. Cancer Epidemiol. 2025 Jun;96:102778. doi: 10.1016/j.canep.2025.102778. Epub 2025 Mar 8.

  PMID: 40058114 DERIVED

MeSH Terms

Conditions

Neoplasms, Second Primary; Coitus

Condition Hierarchy (Ancestors)

Neoplasms; Sexual Behavior; Behavior

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2021
• First Posted: January 11, 2022
• Study Start: October 25, 2021
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: January 22, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)